Central nervous system (CNS) infections are well recognized manifestations of disseminated aspergillosis observed in about 10% of immunocompromised patients and with mortality rates greater than 90%.[@bib1], [@bib2] By contrast, *Aspergillus* meningitis is a more seldomly encountered clinical entity and it is found more frequently in immunocompetent rather than in immunocompromised hosts.[@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8] Information about *Aspergillus* meningitis is limited and sparse and to our knowledge no review on this topic has been published so far. We present here a case of *Aspergillus* meningitis, along with a review of published cases since 1973.

Methods {#sec1}
=======

Case reports of *Aspergillus* meningitis, meningoencephalitis, arachnoiditis and ventriculitis as well as series of CNS aspergillosis were identified through a search of PubMed and Scopus databases of the English literature, and the reference lists were reviewed for additional cases. Research was conducted from the year 1973 through 2011. Used research terms included "*Aspergillus* meningitis", "cerebral aspergillosis", "central nervous system aspergillosis", "*Aspergillus* arachnoiditis", "mycotic meningitis". For the purpose of this review a case of meningitis or meningoencephalitis caused by *Aspergillus* spp. was defined during life as follows: 1) a cerebrospinal culture positive for *Aspergillus* spp. together with a meningeal or encephalic syndrome; 2) the presence of galactomannan antigen or *Aspergillus* DNA detected by polymerase chain reaction (PCR) test in the CSF, together with a meningeal syndrome. *Post-mortem* diagnoses of *Aspergillus* meningitis were included if the autopsy clearly indicated involvement of the meninges or a picture of meningitis with microscopic identification of *Aspergillus* hyphae or a positive *Aspergillus* culture. When inflammation involved the spinal leptomeninges the case was classified as spinal arachnoiditis. Patients were considered immunocompromised if the following conditions were met: 1) HIV/AIDS infection; 2) solid organ transplantation; 3) hematologic diseases with or without bone marrow transplantation; 4) autoimmune diseases treated with steroids or other immunosuppressive drugs; 5) diabetes mellitus; 6) any other condition treated with corticosteroids or immunosuppressive drugs.

Case report {#sec2}
===========

A 34-year-old man was referred to our Infectious Diseases ward on February 9, 2010 from a Neurosurgery Unit where a diagnosis of *Aspergillus* meningitis had been made ([Fig. 1](#fig1){ref-type="fig"} ). The clinical history was notable for heroin intravenous drug abuse, high alcohol intake, untreated chronic hepatitis C and methadone maintenance therapy (50 mg/day). One month before he was admitted to the Internal Medicine ward of another Hospital to investigate the nature of low back pain, headache and low grade fever (37.5 °C) that had appeared 1 month earlier. Magnetic resonance imaging (MRI) of the brain was negative for parenchimal and meningeal lesions. On the contrary, MRI of the lumbar spine showed abnormal contrast enhancement into the spinal canal between L4 and S1 suggesting an intradural mass lesion conditioning a traction effect on the roots of the *cauda equina*. A color-doppler echocardiogram showed only a mild mitral regurgitation. Blood and urine cultures were negative as well as a serologic test for HIV. Cerebrospinal fluid (CSF) analysis performed on February 9 is shown in [Fig. 1](#fig1){ref-type="fig"}. Gram and Ziehl-Neelsen stains, as well as bacterial and mycobacterial cultures, were negative as was the search for bacterial and *Cryptococcus neoformans* antigens. Cerebrospinal culture grew *Aspergillus flavus* that was susceptible to amphotericin B, voriconazole, posaconazole, itraconazole and caspofungin. *Aspergillus* galactomannan antigen-GM (Platelia *Aspergillus*, Sanofi Diagnostics Pasteur, Marne-La Coquette, France) was detected both in the CSF and blood with a higher index value in the former (respectively, 7.4 and 2.5). Upon admission to our ward (February 12), the patient had fever (38.5 °C), was alert and complained of frontal headache and photophobia, without neck stiffness. Intravenous treatment with voriconazole was started (6 mg/kg every 12 h (q12h) as loading dose, followed by 4 mg/kg q12h) together with ceftriaxone (2 g q12). Two weeks later, a control brain and spinal MRI showed meningeal enhancement with cysternal distribution especially in the pre-pontine area around the basilar artery, together with endocanalar pathologic enhancement between L4 and S2 ([Figure 2](#fig2){ref-type="fig"}, [Figure 3](#fig3){ref-type="fig"} a and b). A concomitant CSF analysis showed a reduction of WBCs (180/μL, 61% PMNs), improvement of glucose levels (24 mg/dL, serum 110 mg/dL) and a striking increase of protein level (3705 mg/dl), whereas, at this time point, CSF culture turned negative. The GM index was 6.36 in the CSF and 0.9 in the peripheral blood. Because of persistent fever, headache and worsening of the radiological picture, caspofungin (70 mg loading dose, 50 mg maintenance dose) was added to the antifungal regimen with discontinuation of the antibiotic therapy. Voriconazole blood and CSF trough concentrations obtained after 2 weeks of therapy were similar (5.85 and 5.86 mg/L, respectively). Therapeutic drug monitoring was arranged 6 and 10 days later and it showed toxic concentrations of the drug that prompted dosage adjustments despite the absence of any clinical or biochemical signs of voriconazole toxicity. Another CSF examination performed on March 18, disclosed an improvement of all parameters ([Fig. 1](#fig1){ref-type="fig"}). Repeated MRI of the brain and spine (March, 17) showed the reduction of the pial and cysternal contrast enhancement but a progression of the endocanalar inflammation now involving the segments L3 to S2. After a new evaluation by the neurosurgery consultant, who deemed any procedure unfeasible, the patient was discharged after having received 38 days of voriconazole therapy (total cumulative dosage: 21,200 mg) and one month of caspofungin (total cumulative dosage:1520 mg). The patient was left on maintenance therapy with oral voriconazole at a dosage of 150 mg q12 due to raised ALT levels (199 U/L), the appearance of visual disturbances and persistently elevated trough voriconazole concentrations (6.2 mg/L). At the end of April, the patient was readmitted to our hospital ward because of persistent abnormal liver function test results and visual disturbances that required discontinuation of voriconazole and its substitution with intravenous liposomal amphotericin B (L-AMB, 250 mg/day). He complained of persistent low back pain that was irradiated to both the lower extremities with preserved deep tendon and superficial reflexes. Repeated attempts to obtain CSF samples by lumbar puncture were unsuccessful. Nerve conduction and electromyography studies showed mild sensorimotor bilateral demyelinating polyneuropathy. A new MRI of the brain and spine (performed on May, 17) was substantially unchanged. During the 30-day therapy with L-AMB, GM was evaluated weekly and showed values ranging from 0.9 to 1.59. Because of the patient\'s drug addiction history, it was decided to resume oral voriconazole therapy since the positioning of a permanent intravenous device for L-AMB infusion on an outpatient basis was judged risky. A dosage of 150 mg every 12 h was started on June 9, showing after a week trough and peak concentrations of 3.4 and 3.6 mg/L, respectively. A new MRI of the brain and spine was performed on August 4, that demonstrated a reduction of pial enhancement along the cervical tract, the *conus medullaris* and *cauda equina* with a only a mild volumetric reduction of the endocanalar lumbar abscess. Clinically, the patient was well oriented with a positive bilateral *Lasègue* sign at the neurologic examination. He was discharged and subsequently lost to follow-up.Figure 1Medication history, clinical course and kinetic of *Aspergillus* antigen in CSF of our case of *Aspergillus flavus* meningitis. The dotted line represents the cut-off value of GM. The light blue line is the index on CSF and the red line on plasma. The blue circle represents the CSF levels of voriconazole. The purple diamond and the yellow triangle are respectively the down and peak plasma levels of voriconazole. The blue rectangle denotes the range of expected therapeutic levels of voriconazole.Figure 2Sagittal and coronal T1-weighted gadolinium-enhanced magnetic resonance scan of the brain of our patient with *Aspergillus flavus* meningitis showing contrast impregnation along the basilar artery in the prepontine cistern.Figure 3Sagittal T2 (a) and gadolinium enhanced T1-weighted (T1W) (b) MRI demonstrate pathologic enhancement and endocanalar pathologic tissue of the L4-S2 tract.

Results {#sec3}
=======

A detailed, chronologically ordered summary of 93 cases of *Aspergillus* meningitis, chronic meningitis/pachymeningitis, meningoencephalitis, arachnoiditis and ventriculitis including the one presented herein (case 46) is shown in [Table 1](#tbl1){ref-type="table"} . There were 46 women (50%) and 46 men, with a median age of 37 years (range 3--75 years). Diagnosis was made during life in 52 patients (55.9%) and at autopsy in 41 patients. A diagnosis was obtained more frequently during life among immunocompetent patients (69%) in comparison with immunocompromised individuals (39%) ([Table 2](#tbl2){ref-type="table"} ).Table 1Characteristics of patients with *Aspergillus* meningitis.Author, year \[Reference\]Age/sexRisk factor/Underlying diseaseSign and symptoms (time duration)/Time from TXSyndromeDiagnosis/methodsCSF characteristicsAspergillus speciesCSF Ag GMN (method)Antifungal treatment (time duration)OutcomeMeningitisAtkinson & Israel, 1973[@bib9]27/MNone/SarcoidosisHeadache, blurred visionMeningitisL/CSFWBC 144/μL (PMNs 10%)*Aspergillus fumigatus* (CSF)NA5-FLU (3 months)Alive 2 years after stopping antifungal therapyFeely et al., 1977[@bib10]57/FNeurosurgery (Trans-sphenoidal Yttrium[@bib90] implant)/AcromegalyMeningeal signs, left hemiparesis/11 monthsMeningitisPm/Autopsy (purulent basal leptomeningitis + multiple infarcts)WBC 138/μL (PMNs 96%); proteins 850 mg/L*Aspergillus* spp. (autopsy culture)NANoneDeath after 1 day37/MNeurosurgery (Trans-sphenoidal Yttrium[@bib90] implant)/Diabetic retinopathyFever, stiff neck, headache, blurred vision/9 monthsMeningitisL/Biopsy (tissue adherent to the screws)WBC 8800/μL (PMNs 90%); protein 330 mg/L*Aspergillus* spp. (biopsy)NAAMFB (NR)+ removal of implantAliveMohandas et al., 1978[@bib11]38/MNeurosurgery/Maxillary sinusitisMeningeal irritation, coma/6 days post-operativelyMeningitisL/Surgery of fungal granulomaWBC 100/μL (PMNs 0%); glucose 35 mg/dL; protein 1160 mg/L*Aspergillus* spp. (biopsy)NAAMFB (7 days) ev + intratechal (1 day)Death after 7 daysAung et al., 1979[@bib12]22/FPregnancy/NoneHeadache, retrobulbar pain, blurred vision, ophthalmoplegia (22 days after delivery)MeningitisL/Biopsy leptomeningesND*Aspergillus* spp. (biopsy)NAAntifungal drugs (not mentioned)Death after 1 monthBeal et al., 1982[@bib13]47/FNone/Sphenoid sinusitisFrontal headache (5 months); nuchal rigidity, fever, hydrocephalusMeningitisL/biopsy sinusWBC 120/μL (PMNs 63%); glucose 25 mg/dL; protein 620 mg/L*Aspergillus* spp. (sinus biopsy)NAAMFB (NR)Alive 2 years later22/FNeurosurgery/Medullo-blastomaFever (38.8 °C), severe headache, meningismus 12 days after neurosurgeyMeningitisL/CSF; Autopsy (basilar *Aspergillus* meningitis with exudate in the subarachnoid space of spinal cord)WBC 2650/μL (PMNs 10%); glucose 26 mg/dL; protein 1750 mg/L*Aspergillus* spp. (CSF culture after multiple attempts)NAAMFB (3 days)Death after 20 daysDiendogh et al., 1983[@bib14]60/MNeurosurgery (Trans-sphenoidal Yttrium[@bib90] implant)/Diabetic retinopathyDrowsy, disoriented in time and space, neck stiffness, positive Kernig signMeningitisPM/Autopsy (meningitis; necrotizing vasculitis (pons); fungal invasion of basilar and middle cerebral arteries)WBC 323/μL (PMNs 60%)*Aspergillus* spp. (autopsy histology)NANoneDeath after 2 weeksWalsh et al., 1985[@bib8]64/FSteroid treatment/Cushing syndromeMeningismus,headache, hemiparesisMeningitisPm/Autopsy : mycotic *Aspergillus* aneurism & subarachnoid hemorrhageWBC 15/μL (PMNs 0%); glucose 90 mg/dL; protein 1450 mg/L*Aspergillus* spp. (autopsy histology)NANoneDeath after 9 daysHajjar et al., 1987[@bib15]28/MNeurosurgery/Acoustic neurinomaNR/9 daysMeningitisL/Wound cultureNR*Aspergillus fumigatus* (wound culture)NAAMFB + 5-FLU (2 months)Death after 2 monthsAsnis et al., 1988[@bib16]44/MNone/AIDSConfusion, generalized seizuresMeningitisPm/Autopsy (*Aspergillus* leptomeningites)NR*Aspergillus* spp. (autopsy histology)NAAMFB (20 days)DeathCarrazana et al., 1991[@bib17]44/MNone/AIDS; sphenoid sinusitisHeadache, fever, nausea, ataxia, hemiparesis, seizuresMeningitisPm/Autopsy (*Aspergillus* meningeal infiltration; thrombosis of basilar artery)NR*Aspergillus* spp. (autopsy histology)NANoneDeathKomatsu et al., 1991[@bib18]61/FNeurosurgery/Rathke'cleft cystHigh fever and meningeal signs/12 days after surgeryMeningitisPm/Autopsy (*Aspergillus* meningitis & mycotic aneurism, subarachnoid hemorrhage)WBC 881/μL (PMNs 70%); glucose 46 mg/dL; protein 540 mg/L*Aspergillus* spp. (autopsy histology)NANDDeath after 23 daysLammens et al., 1992[@bib19]39/FImmunosuppressive therapy/SLEHeadache (1 month), fever (39.5 °C), neck stiffness, Horner syndromeMeningitisPm/Autopsy (*Aspergillus* basal meningitis & subarachnoid hemorrhage)WBC 3750/μL (PMNs 84%); glucose 32 mg/dL; protein 1000 mg/L*Aspergillus* spp. (autopsy histology)NANoneDeath after 15 daysTorre-Cisneros et al., 1993[@bib20]31/FLiver transplant/End stage liver diseaseSeizure[a](#tbl1fna){ref-type="table-fn"}MeningitisPm/Autopsy (ischemic infarct; leptomeningeal aspergillosis)NR*Aspergillus* spp. (autopsy histology)NANRDeath21/FLiver transplant/End stage liver diseaseNR[a](#tbl1fna){ref-type="table-fn"}MeningitisPm/Autopsy (ischemic infart; leptomeningeal aspergillosis)NR*Aspergillus* spp. (autopsy histology)NANRDeath24/FLiver transplant/End stage liver diseaseSeizure[a](#tbl1fna){ref-type="table-fn"}MeningitisPm/Autopsy (acute leptomeningitis)NR*Aspergillus* spp. (autopsy histology)NANRDeath38/MKidney transplant/End stage kidney diseaseSeizure[a](#tbl1fna){ref-type="table-fn"}MeningitisPm/Autopsy (acute leptomeningitis; haemorrhagic infarcts)NR*Aspergillus* spp. (autopsy histology)NANRDeathMiaux et al., 1995[@bib21]41/MBone marrow transplant; steroid therapy/CMLFever (38 °C), hemiplegia/2 monthsMeningitisPm/Autopsy (thickening and meningeal inflammation with haemorrhagic necrosis; lung & heart involvement)WBC 2000/μL (PMNs 95%); protein 900 mg/L*Aspergillus* spp. (autopsy histology)NANRDeath after 5 days39/FBone marrow transplant; steroid therapy/RAEBMental confusion/3.5 monthsMeningitisPm/Autopsy (brain hemorrhagic necrosis; lung involvement)WBC 2560/μL (PMNs 98%);*Aspergillus* spp. (autopsy histology)NANRDeath after 8 daysAdunsky et al., 1996[@bib22]74/MNone/NoneFever (38.3°), stuporous, left hemiplegia, dysarthria (1 day)MeningitisL/CSFWBC 2400/μL (PMNs 94%); glucose 10 mg/dL; protein 1500 mg/L*Aspergillus flavus* (CSF culture)NAAMFB (few days)Death after few daysDarras-Joly et al., 1996[@bib23]68/MNeurosurgery/Metastatic cancerAllucinations, disorientation, hemyanopsia/5 months after surgeryMeningitis; extradural empyema; abscessesL/Surgery extradural abscessNR*Aspergillus fumigatus* (extradural abscess)Negative (NR)AMFB (2 months)+ itraconazole (2 months)Death after 12 months29/MNeurosurgery/Acoustic neurinomaFever (38 °C), severe headache/3 days after surgeryMeningitis; abscess;L/CSFWBC 830/μL (PMNs 53%); glucose 48 (s 155) mg/dL; protein 830 mg/L*Aspergillus fumigatus* (CSF culture)Positive (NR)L-AMB (5 weeks)+ 5-FLU (7 weeks); itraconazole (6 months)Alive after 12 monthsMonlun et al., 1997[@bib24]75/FSteroid therapy/AsthmaFever (38 °C); acute respiratory failure (22 days)MeningitisPm/Autopsy (right haemorragic infarct with subcortical vessel invasion and meningeal diffusion by *Aspergillus*; pulmonary involvement)ND*Aspergillus* spp. (autopsy histology)NDAMFB (3 weeks)Death 22 days laterVerweij et al., 1999[@bib25]73/FMastoidectomy/Otitis mediaFever (39 °C), headache, vomiting, drowsiness, meningismus/NRMeningitisL/CSF (sixth attempt)WBC 2130/μL; glucose 27 mg/dL (47 mg/dL serum); protein 150 mg/L*Aspergillus fumigatus* (CSF culture, 6th attempt + PCR)10.4 (Platelia)Itraconazole 1 week; AMFB (4weeks + AMFB intraventricular; voriconazole (9 weeks)Alive 12 months after voriconazole discontinuationMariushi et al., 1999[@bib26]43/FNone/NoneHeadache, neck stiffness (11 days), fever (37.6 °C), nausea, chillsMeningitisL/CSFWBC 329/μL (PMNS 0%); glucose 46 mg/dl; protein 500 mg/L*Aspergillus* spp. (CSF culture, 5th attempt)NDFluconazole (2 years)Alive after 2 yearsArabi, 2001[@bib27]58/MNone/Maxillary sinusitisConfusion, progressive unresponsiveness, 4th nerve palsy 8 days after pneumoniaMeningitisL/Sinus aspirate/Autopsy (*Aspergillus* ventriculitis, meningitis; focal encephalitis; pneumonia)WBC 3500/μL (PMNs 91%); glucose 77 mg/dL(s 102); protein 3370 mg/L*Aspergillus fumigatus* (sinus culture)NDAMFB (3 weeks)Death 20 days laterNenoff et al., 2001[@bib28]74/MEthmoidectomy and orbitotomia (for *A.fumigatus* orbital and sinus infection)/Diabetes mellitusVomiting, nausea, exophthalmus, somnolent and disoriented/7 monthsMeningitisL/Biopsy (orbital apex)/Autopsy *(Aspergillus* meningitis, vasculitis internal carotid, mycotic aneurism with subarachnoid hemorrhage)NR*Aspergillus fumigatus* (biopsy)1:2 (Pastorex)AMFB+ 5-FLU (few days)Death 3 weeks after surgical procedureMoling et al., 2002[@bib29]24/MKidney transplant (reject); Hemodialysis + steroid therapy/complement 4 deficiencyFever (39 °C); confusion; disorientation; right motor hemi-syndrome (2 weeks)MeningitisL/CSFWBC 3200/μL; glucose 4 mg/dL*Aspergillus fumigatus* (CSF culture, 4th attempt + PCR)NDFluconazole (2 weeks): L-AMB (3 weeks); itraconazole (4 months)Alive after 7 months; Death after 6 years[b](#tbl1fnb){ref-type="table-fn"}Kleinschmidt-De Masters, 2002[@bib30]40/FSteroid therapy/Wegener\'s granulomatosisNRMeningitisPm/Autopsy (*Aspergillus* acute and chronic basilar granulomatous meningitis; mycotic aneurism; lung, skin, heart involvement)NR*Aspergillus* spp. (autopsy histology)NDNRDeath after 68 days51/MChemotherapy/LymphomaNRMeningitisPm/Autopsy (*Aspergillus* basilar meningitis; thrombotic occlusion of arteriesNR*Aspergillus* spp. (autopsy histology)NDNRDeath after 4 daysPandian et al., 2004[@bib31]34/FSpinal anaesthesia/NoneFever, headache, vomiting[c](#tbl1fnc){ref-type="table-fn"}MeningitisPm/Autopsy (*Aspergillus* meningitis; mycotic aneurism with subarachnoid hemorrhage)WBC 640/μL (PMNs 76%); glucose 32 mg/dL; protein 3600 mg/L*Aspergillus* spp. (autopsy histology)NDNoneDeath21/FSpinal anaesthesia/NoneFever, headache, vomiting[c](#tbl1fnc){ref-type="table-fn"}MeningitisPm/Autopsy (*Aspergillus* meningitis; mycotic aneurism with subarachnoid hemorrhage)WBC 678/μL (PMNs 65%); glucose 23 mg/dL; protein 3600 mg/L*Aspergillus* spp. (autopsy histology)NDNoneDeath42/FSpinal anaesthesia/NoneFever, headache, vomiting[c](#tbl1fnc){ref-type="table-fn"}MeningitisPm/Autopsy (*Aspergillus* meningitis; mycotic aneurism with subarachnoid hemorrhage)WBC 240/μL (PMNs 68%); glucose 23 mg/dL; protein 2400 mg/L*Aspergillus* spp. (autopsy histology)NDNoneDeath32/FSpinal anaesthesia/NoneFever, headache, vomiting[c](#tbl1fnc){ref-type="table-fn"}MeningitisPm/Autopsy (*Aspergillus* meningitis; mycotic aneurism with subarachnoid hemorrhage)WBC 345/μL (PMNs 76%); glucose 23 mg/dL; protein 1230 mg/L*Aspergillus* spp. (autopsy histology)NDNoneUnknown24/FSpinal anaesthesia/NoneFever, headache, vomiting[c](#tbl1fnc){ref-type="table-fn"}MeningitisPm/Autopsy (*Aspergillus* meningitis; mycotic aneurism with subarachnoid hemorrhage)WBC 435/μL (PMNs 96%); glucose 32 mg/dL; protein 4200 mg/L*Aspergillus* spp. (autopsy histology)NDNoneDeath after 18 monthsLarson Kolbe et al., 2007[@bib32]51/FEpidural steroid injections/COPDMental status changes; 3rd nerve palsy/2 monthsMeningitisL/Disc aspirationNR*Aspergillus fumigatus* (disc aspiration + vpsoas abscess culture)NDCaspofungin + oriconazole (4 months)Death after 5 monthsGunaratne et al., 2007[@bib33], [@bib78]26/FSpinal anesthesia (Pregnancy)/NoneLow grade fever; headache; nausea; vomiting 12 days after saMeningitisPm/AutopsyWBC 302/μL (PMNs 99%); glucose 56 mg/dl (s 115 mg/dL)[d](#tbl1fnd){ref-type="table-fn"}; protein 680 mg/L*Aspergillus fumigatus* (autopsy culture)NDFluconazoleDeath after 4 weeks21/F[e](#tbl1fne){ref-type="table-fn"}Spinal anesthesia (Pregnancy)/NoneFever, chills, neck stiffness 10 days after saMeningitisPm/AutopsyWBC 575/μL (PMNs 70%); glucose 25 mg/dl (s 90 mg/dL)[d](#tbl1fnd){ref-type="table-fn"}; protein 490 mg/L*Aspergillus fumigatus* (autopsy culture)NDAMFB (4 days)Death after 4 weeks27/FSpinal anesthesia (Pregnancy)/NoneFever, headache, neck stiffness; diplopia, photophobia 15 days after saMeningitisL/CSF (microscopy)WBC 720/μL (PMNs 3%); glucose 21 mg/dl (s 133 mg/dL)[d](#tbl1fnd){ref-type="table-fn"}; protein 680 mg/L*Aspergillus* spp. (CSF)NDAMFB iv + it (4 weeks) voriconazole (4 weeks)Alive after 12 months (residual 6th cranial nerve palsy and impaired hearing)29/FSpinal anesthesia (Pregnancy)/NoneFever, headache, vomiting, neck stiffness, photophobia 11 days after saMeningitisL/CSFWBC 1430/μL (PMNs 40%); glucose 45 mg/dl; protein 330 mg/L*Aspergillus fumigatus* (CSF culture)NDAMFB iv + it (2 weeks); voriconazole (16 weeks)Alive after 12 months (no disability)38/FSpinal anesthesia (Pregnancy)/NoneFever, neck stiffness 8 days after saMeningitisPm/AutopsyWBC 225/μL (PMNs 0%); glucose 61 mg/dL (s 109 mg/dL)[e](#tbl1fne){ref-type="table-fn"}; protein 280 mg/L*Aspergillus fumigatus* (autopsy culture)NDAMB (9 days)Death after 24 daysSaitoh et al., 2007[@bib34]33/MChemotherapy/AMLFever, headache, neck stiffness/14 days post-chemotherapyMeningitisL/CSFWBC 15/μL; glucose 30 mg/dL; protein 760 mg/L*Aspergillus* spp. (PCR + Ag on CSF)2.2 (s 0.1) (Platelia)AMFB (1 week); voriconazole (12 months)Alive after 1 yearSundaram et al., 2007[@bib35]22/MSpinal anesthesia (1 month prior)/NoneFever, headache, vomiting (2 months), neck stiffnessMeningitisPm/Autopsy (*Aspergillus* purulent meningitis & mycotic aneurism with subarachnoid hemorrages)WBC 720/μL (PMNs 90%); glucose 37 mg/dL; protein 850 mg/L*Aspergillus fumigatus* (CSF culture, 5th attempt)[f](#tbl1fnf){ref-type="table-fn"}NDNDDeath after 68 daysVan de Beek et al., 2008[@bib36]56/MKidney-pancreas transplant/End stage disease; sphenoid sinusitisHeadache, fever (6 weeks); neck stiffness, dysarthria, hemiparesisMeningitisL/sphenoid biopsy/Autopsy (*Aspergillus* meningitis; midline herniation, subarachnoid hemorrhage)WBC 1200/μL (PMNs 94%); glucose 64 mg/dL; protein 7300 mg/L*Aspergillus fumigatus* (sphenoid biopsy + autopsy)6.47 (s 0.39) (Platelia)Voriconazole (NR)Death after 4 weeks\[PR\], 201135/MIVDA (heroin)/Chronic hepatitis CFever (37.5 °C), headache, back pain (1 month)Meningitis & spinal arachnoiditisL/CSFWBC 260/μL (PMN 70%); glucose 1 mg/dL (s 76 mg/dL); protein 7900 mg/L*Aspergillus flavus* (CSF culture)7.4 (s 2.5) (Platelia)Voriconazole 5 months (+1 month caspofungin); L-AMB 3 monthsAlive after 9 monthsChronic meningitis/pachimeningitisPalo et al., 1975[@bib37]69/MNone/DiabetesHeadache, fever, diplopia, vertigo hearing loss (6 months)Chronic meningitisPm/CSF; autopsy: (granulomatous leptomeningitis and spinal cord involvement)WBC 103/μL (PMNs 8%); glucose 45 mg/dL; protein 1400 mg/L*Aspergillus fumigatus* (CSF culture, 6th attempt)[f](#tbl1fnf){ref-type="table-fn"}NANoneDeath 1 month laterGordon et al., 1976[@bib3], [@bib79]34/FIVDA (heroin, cocaine)/NoneBifrontal headache, neck stiffness (weeks), low-grade feverChronic meningitisL/CSFWBC 2892/μL (PMNs 80%); glucose 16 (s 110) mg/dL; protein 990 mg/L;*Aspergillus oryzae* (CSF culture, 7th attempt)NAAMFB+ 5-FLU (12 months)Alive (6 year later; episode of bilateral necrotizing scleritis due to *A.orizae*)[g](#tbl1fng){ref-type="table-fn"}Mielke et al., 1981[@bib38]58/FNeurosurgery/AcromegalySevere headache (4 months), retro-orbital pain, blindness, ophalthalmoplegia/10 monthsChronic meningitisPm/Autopsy (chronic basilar meningitis by *A.fumigatus* & *C.albicans*; mycotic aneurism of the basilar artery with subarachnoid hemorrhage)ND*Aspergillus fumigatus* (autopsy culture)NANoneDeath after 7 daysWeinstein et al., 1982[@bib39]67/MNone/noneRetro-orbital and periorbital pain, vertigo (months); decrease eye vision; weakness; malaiseChronic meningitisL/biopsy sphenoid wingWBC 88/μL (PMNs 6%); glucose 53 (s 97) mg/dL; protein 1130 mg/L*Aspergillus fumigatus* (biopsy + culture sphenoid)NAAMFB + rifampicin (2 weeks)Death after 18 days from surgerySalaki et al., 1984[@bib40]32/MSteroid treatment/SLEFever (38 °C), frontal headache, lethargy (3 weeks), stiff neck, 6th nerve palsyChronic meningitisL/CSF + spinal aspirateWBC 1400/μL (92%); glucose 33 mg/dL; protein 1100 mg/L*Aspergillus fumigatus* (CSF culture, 4th attempt)NAAMFB +5-FLU (NR)AliveWoods et al., 1990[@bib41]44/MNone/AIDSHeadache, fever, nausea, vomiting, lethargy, slurred speech, severe back pain (4 months)Chronic meningitisPm/Autopsy (*Aspergillus* acute and chronic basilar meningitis; spinal arachnoiditis; pleural, brain, lumbar spinal cord involvement)WBC 80/μL (PMNs 80%); glucose 19 mg/dL; protein 2000 mg/L*Aspergillus fumigatus* (autopsy culture)NANoneDeath after 18 daysMurai et al., 1992[@bib42]59/FNone/Diabetes; Liver cirrhosis; Mondini\'s anomaly; otitis mediaHeadache; hearing loss; multiple nerve palsy (6th, 8th, 9th, 10th, 11th)Chronic pachymeningitisL/surgery maxillary sinusWBC 7/μL; protein 660 mg/L*Aspergillus flavus* (surgery culture)NAMiconazole (2 months); 5-FLU, fluconazole (1 month)Alive after 4 monthsKurino et al., 1993[@bib43]63/MNone/Diabetes; otitis mediaFever, headache, hyperesthesia of face, abducens palsy, deafnessChronic meningitisPm/Biopsy granuloma + autopsyWBC 138/μL (PMNs 50%); glucose 87 mg/dL; protein 1007 mg/L*Aspergillus* spp. (biopsy + autopsy)NANoneDeath 30 days post-surgeryMochizuki et al., 2000[@bib44]75/MNone/Otitis mediaMultiple cranial nerve palsy (2nd, 3rd, 4th), impaired vision (4 months)Chronic pachymeningitisL/BiopsyNR*Aspergillus flavus* (biopsy culture)NDFluconazole (4 weeks); AMFB (4 months)+5-FLU (4 months); itraconazole (5 months)Alive after 36 monthsMoling et al., 2002[@bib29]48/MAlcohol abuse/NoneHeadache, fever, gait instability, apathy (5 months)Chronic meningitis + ventriculitis + arachnoiditisL/CSFWBC 1880/μL; glucose 20 mg/dL*Aspergillus candidus* group (CSF culture)6.7 (s 1.7) (Platelia)AMFB (1 week); rifampicin (several months); voriconazole (10 days); itraconazole (10 months)Alive after 24 monthsKowacs et al., 2004[@bib45]26/MNear drowning/NoneFever (37.2 °C), mild meningismus (4 weeks)Chronic meningitisL/CSFWBC 165/μL (PMNs 69%); glucose 64 mg/dL; protein 778 mg/L*Aspergillus fumigatus* (CSF culture, 3rd attempt)NDFluconazole (12 days); itraconazole + AMFB (44 days)Death after 56 daysIsmail et al., 2007[@bib46]73/MNone/Diabetes mellitus; pulmonary asbestosisHeadache, left-sided visual loss, scalp tenderness, fatigue (3 weeks)Hypertrophic pachymeningitisL/Meningeal biopsyWBC 0/μL; protein 5670 mg/L*Aspergillus flavus* (biopsy culture)NDAntifungal treatment (NR)Death 3 months laterKagawa et al., 2008[@bib47]33/FSpinal cord mass lesionHeadache, low grade fever (5 months), hydrocephalusChronic meningitisL/Biopsy VA shuntWBC 1340/μL; glucose 8 mg/dL; protein 1580 mg/L*Aspergillus* spp. (VA shunt biopsy)NDAMFB (NR); fluconazole (NR)Alive after 15 years (multiple recurrences)Chan et al., 2011[@bib48]59/MDiabetes; impaired renal functionHeadache, diplopia, hoarseness (2 months)PachymeningitisL/Dural biopsyGlucose 102 mg/dL; protein 1270 mg/L*Aspergillus flavus* (culture from dural biopsy)Positive (β-[d]{.smallcaps}-glucan + Platelia)Voriconazole (2 weeks); caspofungin (4 weeks); voriconazoleAlive after 7 monthsKato et al., 2011[@bib49]42/MNone/NoneHeadache, right nucal pain, cranial nerve palsies[@bib9], [@bib10], [@bib11], [@bib12] (2 months)Hypertrophic pachymeningitisL/CSFWBC 43/μL (PMNs 4%); glucose 56 mg/dL; protein 1000 mg/L*Aspergillus* spp. (CSF PCR positive)β-[d]{.smallcaps}-glucan (Fungitell) 164 pg/mL; serum \< 5 pg/mLVoriconazole (8 week)s; L-AMB+ 5-FLU( 2 week)s; fluconazole 8 weeksAlive after 30 months**Meningoencephalitis**Goldhammer et al., 1974[@bib50]45/MNone/noneHeadache (9 months), blurred vision (3 weeks)MeningoencephalitisPm/Autopsy (disseminated meningoencephalitis with pituitary abscess and left optic nerve involvement)ND*Aspergillus* spp. (microscopy smear of pituitary abscess + autopsy)NANoneDeath 4 days postoperativelyNaidoff et al., 1975[@bib51]29/FKidney transplant/End stage kidney diseaseNRMeningoencephalitisPm/Autopsy.disseminated aspergillosis (heart, lung, liver, spleen, thyroid, brain, eye, meninges)ND*Aspergillus fumigatus* (autopsy culture)NANoneDeath in a few daysKaufman et al., 1976[@bib52]31/FIVDA (heroin)/NoneHeadache (9 months), blurred vision (2 months), intermittent diplopia, hearing lossMeningo-encephalitisL/Lobectomy; CSF/Autopsy (granulomatous basilar leptomeningitis; aspergilloma left frontal gyrus; transtentorial and tonsillar herniation)WBC 1150/μL (PMNs 83%); glucose 20 (s 119) mg/dL;*Aspergillus fumigatus* (CSF + frontal granuloma culture)NAAMFB (2 weeks)Death after 3 weeksHorton et al., 1976[@bib53]17/FFungal endocarditis/Aortic stenosisHeadache, incoordination, right-sided numbness, seizureMeningoencephalitisPm/Autopsy (mycotic aneurism of the middle cerebral artery with subarachnoid hemorrhage)NR*Aspergillus fumigatus* (CSF culture)NANoneDeath after 9 daysGalassi et al., 1978[@bib54]59/FNeurosurgery/MeningiomaIntermittent fever, seizures, aphasia, hemiparesis/12 monthsMeningoencephalitisL/Surgery of dura granulomas; CSF/Autopsy (diffuse purulent meningo-enecephalitis)NR*Aspergillus fumigatus* (CSF culture)NAAMFB (3 months)Death after 3 monthsPeacock et al., 1984[@bib55]23/MPost-chemotherapy/Refractory anemiaFever, headache, lethargia (57 days post-chemo)MeningoencephalitisL/Biopsy (pulmonary); Autopsy (*Aspergillus* leptomeningitis; necrotizing vasculitis (pons and basal ganglia); tonsillar herniation; necrotizing pneumonia)WBC 117-1126/μL (PMNs 88--99%); glucose 13--48 mg/dL; protein 540--3460 mg/L*Aspergillus terreus* (culture lung biopsy); CSF *Aspergillus* antigenPositive (RIA)AMFB +5-FLU + rifampicin (NR)Death after 65 daysOuammou et al., 1986[@bib56]3/MNeurosurgery/EncephalomeningoceleFever (37.8 °C), frontal subcutaneous abscess/3 daysMeningoencephalitisL/CSF; surgery: meningeal mycetoma. Autopsy: encephalitis (cerebral hemispheres, brain stem)WBC 52/μL (PMNs 70%); glucose 10 mg/dL; protein 1200 mg/L;*Aspergillus fumigatus* (CSF culture)NAGriseofulvin (3 months)Death after 3 monthsCox et al., 1990[@bib57]31/MNone/AIDSHeadache, fever (38.2 °C), confusion, vomitingMeningoencephalitisPM/Autopsy (*Aspergillus* meningitis; mycotic aneurysms; endocarditis; myocarditis)ND*Aspergillus* spp. (autopsy histology)NANoneDeath after few daysBreneman et al., 1992[@bib5]50/MIVDA; steroid therapy/COPDFever (38.6 °C), dyspnea, headache; stiff neck, progressive mental status change (3 days)MeningoencephalitisL/brain biopsyWBC 4100/μL (PMNs 96%); glucose 33 mg/dL; protein 1340 mg/L*Aspergillus fumigatus* (Brain biopsy culture)NAAMFB (few days)Death after few daysVan der Knaap et al., 1993[@bib58]3/MNone/GalactosemiaFever (40 °C), nuchal rigidity, convulsions, left hemiparesisMeningoencephalitisL/CSF positive antigenNormal*Aspergillus* spp.Positive (NR)AMFB + 5-FLU (NR)ImprovementMikolich et al., 1996[@bib6]25/FNone/NoneWorsening headache (3 months); vomiting; photophobia (1 month); papilledemaMeningoencephalitisL/brain biopsyWBC 200/μL (PMNs 2%); glucose 40 mg/dL; protein 920 mg/L*Aspergillus fumigatus* (brain biopsy)NAItraconazole (24 months)Alive after 4 yearsDarras-Joly et al., 1996[@bib23]17/FNeurosurgery/EpendymomaFever (40 °C), neck stiffness/7 days after surgeryMeningoencephalitis; ventricultisL/Surgical drainageWBC 1900/μL (PMNs 97%); glucose 36 mg/dL; protein 1100 mg/L*Aspergillus fumigatus* (surgical culture)Negative (NR)AMFB (72 days) + itraconazole (30 days)Death after 96 daysSchwartz et al., 1997[@bib59]18/MChemotherapy/ALLMeningism, fever/(92 days post-chemotherapy)MeningoencephalitisL/Brain biopsyWBC 1056/μL (PMNs 96%)*Aspergillus* spp. (Brain biopsy)NDItraconazole (4 weeks); voriconazole (6 months)Death after 6 monthsKoh et al., 1998[@bib60]15/FChemotherapy/ALLFlaccid weakness lower extremities, slurred speech, urinary retentionMeningomieloencephalitisPm/Autopsy (Multifocal leptomeningeal exudates; fungal abscess/necrosis in spinal cord)ND*Aspergillus* spp. (autopsy histology)NDNDDeath 21 days laterPayot et al., 1999[@bib61]29/MNone/AIDSHeadache (3 weeks), nausea (1 week), fever (39 °C), nuchal rigidityMeningoencephalitisPm/Autopsy (*Aspergillus* purulent basal meningitis + bulbar encephalitis)WBC 19/μL (PMN 50%); protein 1080 mg/L*Aspergillus* spp. (autopsy histology)NDNoneDeath after 7 daysFasciano et al., 1999[@bib62]26/MSteroid treatment/Chronic asthmaFever, quadriplegia, areflexia; hydrocephalus (2 weeks)MeningoencephalitisL/Brain biopsy/Autopsy: (Aspergillosis of brain, meninges, cauda equina, lungs, thyroid; bilateral uncal herniation)WBC 1300/μL (PMNs 98%); glucose 40 mg/dl; protein 1100 mg/L*Aspergillus fumigatus* (brain biopsy)NDAMFB iv and intratechal + 5-FLU (2 weeks)Death after 6 weeksChandra et al., 2000[@bib63]40/FNone/Ethmoid and sphenoid sinusitisHeadache, fever, vomiting (1 week); left proptosisMeningoencephalitisL/Brain biopsyNR*Aspergillus fumigatus* (biopsy)NDNRNRViscoli et al., 2002[@bib64]NRBMT/Acute lymphoblastic leukemiaFever, neurological deficit, seizures/5 days post-BMTMeningoencephalitisPm/Autopsy (diffuse meningeal and parenchimal infiltration)NR*Aspergillus* spp. (meningeal and parenchimal)578 (s 25.7) (Platelia)NRDeathWang et al., 2003[@bib65]39/MSteroid treatment/SARSTentorial herniationMeningoencephalitisPm/Autopsy: (*Aspergillus* meningitis; multiple brain abscess containing aspergillus; disseminated aspergillosis heart, kidney, spleen, pancreas, adrenal glands)ND*Aspergillus* spp. (autopsy histology and culture)NDNoneDeathRoberts et al., 2004[@bib66]71/FNone/SinusitisFever (38.3 °C), severe headache, diplopia, confusion (5 weeks)MeningoencephalitisPm/Autopsy (*Aspergillus* granulomatous meningitis; thrombosis of basilar artery)WBC 286/μL (PMNs 38%); glucose 23 mg/dL (s 99); protein 850 mg/L*Aspergillus* spp. (autopsy histology)NDNoneDeath after 10 daysBotturi et al., 2006[@bib67]59/FSteroid treatment/Sphenoid sinusitis/Headache, diplopia; bilateral 6th nerve palsy (5 weeks)MeningoencephalitisL/Brain biopsyWBC 920/μL (PMNs 96%); glucose 0 mg/dL; protein 180 mg/L*Aspergillus* spp. (biopsy)NDAMFB (8 weeks); voriconazole (6 months)Alive after 23 monthsGabelmann et al., 2007[@bib68]43/FChemotherapy/AML; sinusitisNRMeningoencephalitisPm/AutopsyNR*Aspergillus* spp. (autopsy histology)NDNRDeath after 41 daysVan de Beek et al., 2008[@bib36]62/FKidney-pancreas transplant/End stage diseaseHeadache (6 months), altered consciousnessMeningoencephalitisL/Autopsy (cerebral aspergillosis)WBC 286/μL (PMNs 90%); glucose 27 mg/dL; protein 830 mg/L*Aspergillus* spp. (autopsy histology)2.72 (s 0.06) (Platelia)ABLCDeath after 12 days**Spinal arachnoiditis**Bryan et al., 1980[@bib69]26/MIVDA (heroin)/NoneHeadache, nausea, vomiting (weeks), low back pain; hydrocephalusSpinal arachnoiditisL/Lumbar biopsy (lesion L3-5)WBC 1857/μL (PMNs 43%); glucose 6 mg/dL; protein 5170 mg/L*Aspergillus flavus* (immunofluorescence on biopsy) (CSF)NAAMFB + rifampicin (10 weeks)Alive after 14 monthsStein et al., 1982[@bib70]24/FIVDA (heroin)/Chronic alcoholismLow back pain (4 months), left leg weakness, frequent headache fever (38 °C); confusion and signs of meningeal irritationSpinal arachnoiditisL/CSFWBC 62/μL (PMNs 30%); glucose 70 (105) mg/dL; protein 350 mg/L*Aspergillus terreus* (2 CSF cultures)[f](#tbl1fnf){ref-type="table-fn"}NAAMFB (NR)Death 26 days after laminectomyVan de Wyngaert et al., 1986[@bib71]30/MNone (splinter stuck on his hand)/NoneHigh fever, painful stiffness of spine, headache, photophobia, nauseaSpinal arachnoiditisL/CSFWBC 3200/μL (PMNs 90%); glucose 30 mg/dL; protein 1530 mg/L*Aspergillus fumigatus* (CSF) precipitinNAAMFB (3 months)+ rifampin (10 days)+ 5-FLU (3 months)Alive after 229 daysEndo et al., 2001[@bib72]55/MNeurosurgery/Pituitary adenomaDiplopia, retro-orbital pain (1 year), loss of vision/9 yearsArachnoiditis; subdural abscessL/Abscess aspirationNR*Aspergillus fumigatus* (abscess culture)NDAMFB + fluconazole (4 weeks)Death after 1 monthGenzen et al., 2009[@bib73]37/FSpinal anesthesia (12 months prior pregnancy)Headache (months); fever (37.4 °C), blurred vision, numbness left lower extremityArachnoiditisL/Laminectomy & tissue biopsyWBC 970/μL (PMN 92%); glucose 50 mg/dL; protein 1010 mg/L*Aspergillus terreus* (biopsy culture)ND (s 0.47)Voriconazole (78 days); voriconazole + caspofungin (54 days); AMFB (6 days); ABLC (50 days)Alive after 9 months**Ventriculitis**Morrow et al., 1983[@bib4]36/MIVDA (heroin)/NoneFever, generalized seizures, nuchal rigidity (1 day)VentriculitisPm/Autopsy (ventriculitis & hydrocephalus)WBC 549/μL (PMNs 27%); glucose 29 (s 90) mg/dl; protein 1200 mg/L*Aspergillus flavus* (serology)[h](#tbl1fnh){ref-type="table-fn"}NANoneDeath after 40 daysHummel et al., 2006[@bib74]4/FChemotherapy/ALLNRVentriculitis & multiple abscessL/CSF (Ommaya reservoir)NR*Aspergillus fumigatus* (PCR CSF)Positive (Platelia)Voriconazole + caspofungin (5 weeks); intraventricular AMFB (4 weeks); voriconazole (2 months)Alive after 3 monthsSutton et al., 2009[@bib75]18/MLung transplant/End stage pulmonary diseaseHeadache, seizure, low grade fever, altered mental statusVentriculitisPm/Autopsy (necrotizing granulomatous inflammation of meninges)WBC 1100/μL (PMN 79%); glucose 41 mg/dL (s 122); protein 1090 mg/L*Aspergillus granulosus* (autopsy culture)NDVoriconazole then ABLC and posaconazoleDeath after 87 daysAntachopoulos et al., 2011[@bib76]5/FVP shuntFever (40 °C), tonic/clonic seizuresVentriculitisL/VPWBC 400/μL (Neutrophil predominance); glucose 25 mg/dL (s 110 mg/dL); protein 1000 mg/L*Aspergillus fumigatus* (Culture VP catheter; PCR CSF)5.5 (Platelia)L-AMB (4 months)+ voriconazole (5 months)Death after 9 months[^1][^2][^3][^4][^5][^6][^7][^8][^9]Table 2Characteristics of patients with aspergillus meningitis.Immunocompetent patients, *n* = 52 (%)Immunocompromised patients, *n* = 41 (%)Total, *n* = 93 (%)Age, years median (range)34.5 (3--73)39 (4--75)37 (3--75)Sex, female (%)34 (65.4)15/40 (37.5)49/92 (53.3)Diagnosis during life36/52 (69.2)16/41 (39)52/93 (55.9)Death after diagnosis in life18/36 (50.0)9/16 (56.3)27/54 (50.0)Total deaths33/52 (63.5)34/41 (82.9)67/93 (72.1)Clinical pictureMeningitis27 (51.9)[a](#tbl2fna){ref-type="table-fn"}19 (46.3)46 (49.5)Meningoencephalitis10 (19.2)13 (31.7)23 (24.7)Chronic meningitis/pachimeningitis8 (15.4)[b](#tbl2fnb){ref-type="table-fn"}7 (17.1)15 (16.1)Spinal arachnoiditis5 (9.6)[c](#tbl2fnc){ref-type="table-fn"}−(0.0)5 (5.4)Ventriculitis2 (3.8)2 (4.9) [d](#tbl2fnd){ref-type="table-fn"}4 (4.3)CSF characteristicsPositive culture17/46 (36.9)4/22 (18.2)21/68 (30.9)Positive PCR3/3 (100)3/3 (100)6/6 (100)Median WBCs/μL (range)640 (5--8800)988 (0--4100)678 (0--8800)Neutrophils predominance (≥60%)25/37 (67.6)14/20 (70)39/57 (68.4)Hypoglicorrachia9/14 (64.3)1/2 (50)10/16 (62.5)Median glucose level (mg/dL)30 (1--77)33 (0--102)32.5 (0--102)Glucose ≤ 25 mg/dl16/39 (41.1)4/17 (23.5)20/56 (35.7)Median protein level (range) (mg/L)995 (100--7900)1090 (180--7300)1007 (100--7900)Median galactomannan antigen (range)7.05 (5.5--10.4)4.58 (2.2--578)6.58 (2.2--578)Positive6/8 (75)7/7 (100)13/15 (86.7)[^10][^11][^12][^13]

In almost half of the cases (*n* = 44) *Aspergillus* was identified by histology or culture without speciation; all other infections were caused by *A. fumigatus* (*n* = 34), *A. flavus* (*n* = 8) and *A. terreus* (*n* = 3) while *A. oryzae*, *A. granulosus* and *A. candidus* were identified in one case each. Forty-one patients were considered immunocompromised hosts (5 AIDS patients; 3 with autoimmune diseases treated with steroids; 9 solid organ transplant recipients; 10 hematologic patients undergoing chemotherapy or bone marrow transplantation; 5 subjects under steroid therapy for chronic obstructive pulmonary disease (COPD), and Severe Acute Respiratory Syndrome; 7 patients with diabetes and, finally, 1 each with Cushing\'s disease and sarcoidosis). In the fifty-two patients without classic risk factors for invasive aspergillosis, central nervous system involvement was presumed to be the result of: direct extension of *Aspergillus* from the orbit, ear or paranasal sinuses in 6 patients (11.5%); iatrogenic direct inoculation of *Aspergillus* through spinal anesthesia (13 patients, 25%), neurosurgery (13 patients, 25%) or epidural steroid injections (1 patient). In six intravenous drug abusers (11.5%) the infection was probably acquired by the hematogenous route. Among the remaining subjects, no predisposing factor could be identified in six patients while one patient each were notable for the presence of the following: pregnancy, alcohol abuse, fungal endocarditis and near drowning. The most common syndrome was acute meningitis which was observed in 46 patients, followed by meningoencephalitis (*n* = 23). A chronic course of meningitis was observed in 15 patients; five patients showed a picture of spinal arachnoiditis (in 1 case with associated meningitis), and 4 ventriculitis ([Table 2](#tbl2){ref-type="table"}). An acute course characterized by rapid deterioration of the clinical picture usually ending with death was observed among immunocompromised hosts and in patients who had direct inoculation of the fungus into the cerebrospinal fluid or the subarachnoid space. By contrast, a sub-acute or chronic form of meningitis going unrecognized for several weeks and sometimes displaying a relapsing character was the most frequent presentation among immunocompetent patients, intravenous drug abusers and patients with diabetes. However, the latter clinical picture was also observed among several patients who had undergone neurosurgery.

Cerebrospinal fluid culture was positive for *Aspergillus* spp. in 31% of cases with a slightly higher prevalence among immunocompetent (36.9%), as opposed to immunocompromised hosts (18.2%) ([Table 2](#tbl2){ref-type="table"}). In nine patients, *Aspergillus* spp. was cultured from CSF only after repeated attempts (median number of lumbar punctures: 4, range 3--9). Antigen-based assays were employed in fifteen patients: GM antigen by use of the Platelia Elisa in 10 patients, with an unspecified assay in 2 patients, with Pastorex assay in 1 patient and 1,3-β-[d]{.smallcaps}-glucan in 2 individuals. GM antigen was detected in CSF specimens of 6 out of 8 immunocompetent patients and in all immunocompromised hosts in whom it was assessed (7/7, 100%) with an overall sensitivity of 86.7%. The median CSF GM index was 6.58 (range 2.2--578).

Serum GM was concomitantly measured in 8 cases and turned positive in 3. In 3 patients, CSF GM was serially determined (3--10, median 7), showing a good correlation with response to therapy. 1-3-β-[d]{.smallcaps}-glucan was evaluated in 2 patients with positive results in both. CSF pleocytosis was detected in 61/64 (95.3%) of available specimens with a median cell count of 678/μL and with a neutrophil predominance in 68.4% of cases. Hypoglycorrhachia was shown to be present in 62.5% of cases with a median glucose level of 32.5 mg/dL.

Fifty-six patients received antifungal therapy : amphotericin B dehoxycholate (AMFB) alone or associated with 5-fluorocytosine (11 pts), rifampicin (5 pts), itraconazole (3 pts) or fluconazole (1pt) was used in 36 cases; liposomal amphotericin B (L-AMB) was employed in the treatment of 6 individuals; fluconazole was used in five patients (in three patients as the only drug). Two patients received 5-fluorocytosine, alone in one case and with miconazole and fluconazole in the other case. Fifteen patients received voriconazole (in three cases associated with caspofungin), and in 4 following AMFB use. AMFB was the main antifungal employed until 1996 when oral itraconazole was used for the first time. Voriconazole and L-AMB were used for the first time in 1997, whereas caspofungin in 2006.

Of those patients who had received at least one dose of antifungal agent, 30 (51.7%) died after an interval of time ranging from few days up to 6 years. All patients with chronic meningitis were initially treated with antibiotics and 6 had also received anti-tubercular therapy. An overall case-fatality rate (CFR) of 72.1% was observed, with significant differences between immunocompetent (63.5%) as opposed to immunocompromised patients (82.9%) patients.

Autopsy was available in 49 cases and it was the method by which diagnosis was made for 40 patients (81.6%). In twelve cases basilar meningitis was identified; spinal cord involvement was observed in 5 patients; the presence of a mycotic aneurism involving either the internal carotid artery or the basilar artery was shown in 12 patients with concomitant subarachnoid hemorrhage. Transtentorial, tonsillar or uncal herniation was present in three patients.

Discussion {#sec4}
==========

In a 1969 review of the literature, Mukoyama et al., reported 33 cases of aspergillosis involving the CNS of whom 10 had meningitis and 3 had meningoencephalitis. However, *Aspergillus* isolation failed in all 10 cultured cerebrospinal fluid specimens.[@bib7]

In a clinical-pathological study of central nervous system aspergillosis only 1 patient had signs of meningeal irritation during life while at autopsy the meninges were focally affected in nearly half of the cases.[@bib8]

In the present series regarding 93 patients, a picture of pure meningitis was observed in 65.6% of cases,[@bib3], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31], [@bib32], [@bib33], [@bib34], [@bib35], [@bib36], [@bib37], [@bib38], [@bib39], [@bib40], [@bib41], [@bib42], [@bib43], [@bib44], [@bib45], [@bib46], [@bib47], [@bib48], [@bib49] while meningoencephalitis was diagnosed in about 25% of patients.[@bib5], [@bib6], [@bib36], [@bib50], [@bib51], [@bib52], [@bib53], [@bib54], [@bib55], [@bib56], [@bib57], [@bib58], [@bib59], [@bib60], [@bib61], [@bib62], [@bib63], [@bib64], [@bib65], [@bib66], [@bib67], [@bib68]

In patients with a diagnosis of meningitis fever and headache were the most common presenting symptoms (78.8%) followed by neck stiffness in 28.2% (24/85).[@bib3], [@bib4], [@bib5], [@bib6], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31], [@bib32], [@bib33], [@bib34], [@bib35], [@bib36], [@bib37], [@bib38], [@bib39], [@bib40], [@bib41], [@bib42], [@bib43], [@bib44], [@bib45], [@bib46], [@bib47], [@bib48], [@bib49], [@bib50], [@bib51], [@bib52], [@bib53], [@bib54], [@bib55], [@bib56], [@bib57], [@bib58], [@bib59], [@bib60], [@bib61], [@bib62], [@bib63], [@bib64], [@bib65], [@bib66], [@bib67], [@bib68], [@bib69], [@bib70], [@bib71], [@bib72], [@bib73], [@bib74], [@bib75], [@bib76] However, only 16.5% (14/85) of patients presented with three of the four signs and symptoms of headache, fever, neck stiffness and altered mental status.[@bib5], [@bib10], [@bib18], [@bib19], [@bib20], [@bib25], [@bib33], [@bib34], [@bib35], [@bib36], [@bib40], [@bib57], [@bib61], [@bib66], [@bib70] Cranial nerve palsies were reported in 17.6% (15/85) and seizures (11/86) in 12.8% of patients.

The diagnosis of *Aspergillus* meningitis is very difficult and challenging. In fact, a diagnosis during life was obtained only in 55.9% of patients although with a much higher frequency among immunocompetent patients (69.2%)[@bib3], [@bib6], [@bib10], [@bib12], [@bib13], [@bib15], [@bib22], [@bib23], [@bib25], [@bib26], [@bib27], [@bib29], [@bib32], [@bib33], [@bib39], [@bib44], [@bib45], [@bib47], [@bib52], [@bib54], [@bib56], [@bib58], [@bib63], [@bib69], [@bib70], [@bib71], [@bib72], [@bib73], [@bib76], [@bib78], [@bib79] ^PR^ as opposed to immunocompromised individuals (39%).[@bib5], [@bib9], [@bib28], [@bib29], [@bib34], [@bib36], [@bib40], [@bib42], [@bib46], [@bib48], [@bib55], [@bib59], [@bib74] This difference might be explained by a more aggressive and acute course of the disease observed in immunosuppressed hosts. A culture-based diagnosis of *Aspergillus* meningitis is hampered by the lack of sensitivity as shown by the 31% of positive results observed in our review of published cases.[@bib3], [@bib9], [@bib13], [@bib22], [@bib23], [@bib25], [@bib26], [@bib29], [@bib33], [@bib35], [@bib37], [@bib40], [@bib45], [@bib52], [@bib53], [@bib54], [@bib56], [@bib70] ^PR^ It has been previously suggested that a minimum of 5 mL of cerebrospinal fluid should be cultured when a mycosis is suspected or that repeated culture of large volumes of CSF are critical for successful *in vitro* isolation. However, such large volumes are not easy to obtain in clinical practice.[@bib80] On the other hand, serial lumbar puncture does indeed seem to have a role since in 9 cases, the fungus could be successfully isolated from cerebrospinal fluid only after several attempts.[@bib3], [@bib25], [@bib26], [@bib29], [@bib35], [@bib37], [@bib40], [@bib45]

Non-culture based diagnostic methods for the diagnosis of aspergillosis were employed on CSF in fifteen patients and seem to outperform traditional culture, with a overall sensitivity of 87%.[@bib23], [@bib25], [@bib28], [@bib29], [@bib34], [@bib36], [@bib48], [@bib49], [@bib64], [@bib75], [@bib76] ^PR^ Although a cut-off value of the GM index has not yet been formally established for the diagnosis of CNS aspergillosis, it has been proposed that it might be lower than that used for serum samples due to the lower back-ground reactivity of CSF.[@bib25], [@bib81]

The median CSF GM index in this series was 6.58 which is a value higher than what is usually observed in serum and well above the cut-off of 0.5 when two serial serum determinations are used among immunocompromised patients or the 0.7--1 value when a single determination is employed in non-hematological patients.[@bib82], [@bib83] Notably, when both serum and CSF GM were screened concomitantly, negative results were observed in three cases in serum and the index value was always higher in CSF than in serum.[@bib29], [@bib34], [@bib36], [@bib64] ^PR^ Although serial determinations on CSF were available only in three cases they may provide useful information on the therapeutic response.[@bib25], [@bib29] ^PR^ Finally, it seems that the Platelia GM test works well irrespective of the species of *Aspergillus* involved as shown by the cases described by Verveij, Moling and ourselves in whom *A. fumigatus*, *A. candidus* and *A. flavus* were respectively cultured from the CSF.[@bib25], [@bib29] ^PR^

Our review shows that *Aspergillus* meningitis has an ominous prognosis with a global case-fatality rate (CFR) of 72.1% but with a much better outcome among immucompetent patients in whom a CFR of 63.5% was observed versus a 83% CFR registered among immunocompromised patients. Our data are only slightly better than the 88% CFR reported by Lin et al. in a literature-based survey published before 2001.[@bib84]

The Infectious Diseases Society of America (IDSA) guidelines recommend voriconazole for the treatment of central nervous system aspergillosis but these recommendations are mainly based upon studies regarding patients with hematological disorders and there is no specific mention as to the treatment of *Aspergillus* meningitis.[@bib85] In our present review, that encompasses a long period of time before the introduction of voriconazole (*i.e*., 2002), most patients (64.3%) were treated with amphotericin B dehoxycholate and less than 30% received voriconazole at some time of their disease.[@bib32], [@bib33], [@bib34], [@bib36], [@bib48], [@bib49], [@bib67], [@bib73], [@bib74], [@bib75], [@bib76] ^PR^ In a recent analysis conducted by Schwartz et al. on 120 cases of CNS aspergillosis a 47% response rate and a median survival of 159 days among patients treated with voriconazole was shown.[@bib86] Voriconazole shows excellent penetration into the CNS as demonstrated by studies conducted in healthy guinea pigs in whom high cerebrospinal fluid to plasma ratio (0.68) together with rapid penetration across the blood brain barrier were observed.[@bib87] Including the present report, determination of cerebrospinal fluid concentrations of voriconazole were available in four cases, with reported values ranging from 0.8 to 5.86 mg/L and with a CSF/plasma ratio ranging from 38% to 76 %.[@bib25], [@bib59] ^PR^ Hope recently proposed that in the busy clinical setting, voriconazole therapeutic drug monitoring (TDM) should be obtained at the end of day 2 and subsequently in the first week of therapy.[@bib88] An association between poor outcome and voriconazole concentrations has been initially observed by Pascual and coworkers.[@bib89] In addition Miyakis et al. recently showed an 11-fold increased risk of death among patients with invasive mycoses treated with voriconazole who had an initial trough concentration of less than 0.35 mg/L.[@bib90] By contrast, several studies and expert opinion suggest that the optimal maximum voriconazole concentrations should not exceed 5.5--5.8 mg/L[@bib89], [@bib91], [@bib92]

Another crucial issue not yet addressed so far is the optimal length of antifungal therapy in patients with *Aspergillus* meningitis, as well as for cerebral aspergillosis. In our patient, antifungal treatment was administered for 7 months, 5 of which employing voriconazole but, just before losing the patient to follow-up we were uncertain how long it would have been necessary to continue the specific treatment. Our analysis of the literature regarding patients with *Aspergillus* meningitis who were treated with voriconazole shows very different lengths of treatment, ranging from 8--14 weeks to 5--12 months.[@bib25], [@bib32], [@bib33], [@bib34], [@bib67], [@bib74], [@bib76] ^PR^

However, it should be pointed out that in most cases the outcome following drug discontinuation is not reported. The long term duration of voriconazole treatment for patients with *Aspergillus* meningitis or with CNS involvement is a matter not only of efficacy but also of toxicity. In this regard, the risk of phototoxicity and, above all, the risk of inducing squamous cell carcinoma should be mentioned.[@bib93]

Caspofungin was employed in 5 patients, (in 4 of whom in combination with voriconazole), but its role, if there is any, as a single agent in the treatment of aspergillus meningitis is hampered by the lack of significant penetration across the blood--brain barrier of this drug.[@bib94] Except one apparently successful case, flucytosine has been used only in association with AMFB and its role in the treatment of aspergillosis remains anecdotal.[@bib9], [@bib95]

In conclusion, our review shows that *Aspergillus* meningitis is a rare clinical entity that is much more frequently observed among immunocompetent patients. It is characterized by CSF neutrophil pleocytosis in 68% of cases and hypoglycorrhachia in 62% of cases. Cultures of CSF are positive only in one third of cases, but the GM antigen test is very useful, with a sensitivity reaching 87%. Although our data show a poor prognosis, we believe that the more widespread use of diagnostic methods with greater sensitivity (*i.e*., PCR and GM), together with the availability of voriconazole therapy, may allow improved outcomes provided that the diagnosis is achieved earlier. The optimal length of antifungal therapy however remains to be determined.
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[^1]: M = male; F = female; IVDA = intravenous drug abuser; CSF = cerebrospinal fluid; L = life; Pm = post-mortem; Ag GMN = galactomannan antigen; s = serum; WBC = white blood cells; PMNs = polymorphonuclear; NA = not available; ND = not done; NR = not reported; AMB = amphotericin B dehoxycholate; 5FLU = 5-fluorocytosine; L-AMB = liposomal amphotericin B; ABLC = amphotericin B lipid complex; ALL = acute lymphoblastic leukaemia; CML = chronic myelogenous leukemia; RAEB = refractory anemia with excess blasts; C4def = hereditary complete C4 deficiency; PR = present report; PCR = polymerase chain reaction; VP = ventriculoperitoneal; sa = spinal anaesthesia.

[^2]: One of these four patients had meningism and headache.

[^3]: Reported also in reference [@bib77] (updated the follow-up).

[^4]: Symptoms appeared 2--21 days after spinal anaesthesia (mean 7.8 days).

[^5]: Random values of blood glucose were reported.

[^6]: Reported also in reference [@bib78].

[^7]: Discarded as contaminant.

[^8]: Reported also in reference [@bib79] (updated the follow-up).

[^9]: Serological speciation made a result compatible with *A. flavus.*

[^10]: 1 patient also had empyema,1 abscess, 1 spinal arachnoiditis.

[^11]: 1 patient had concomitant ventriculitis + arachnoiditis.

[^12]: 1 patient had concomitant subdural abscess.

[^13]: 1 patient had concomitant multiple abscess.
